BioAdaptives, Inc.
BioAdaptives, Inc.
Your view on BDPT
Overview
What the company does, where it operates, and who runs it.
About BioAdaptives, Inc.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- James E. Keener
- Headquarters
- 2620 Regatta Drive, Las Vegas, NV, US
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- James E. Keener
- Headquarters
- 2620 Regatta Drive, Las Vegas, NV, US
BioAdaptives, Inc. markets and distributes natural plant and algal-based products for humans and animals. The company focuses on offering health and wellness products, such as dietary supplements.
It offers PrimiCell, PluriPain, PrimiLungs, PrimiLive, and PrimiSleep, as well as markets Lung Flute for humans; Canine Regen and Equine Regen for dogs and horses, as well as base formulations, including Equine All-in-One to trainers, horse owners and boarding stables; and All-in-One products, which combine minerals, vitamins, amino acids, and other botanicals with the Regen compounds.
The company was formerly known as APEX 8 Inc. and changed its name to BioAdaptives, Inc. in September 2013. BioAdaptives, Inc. was incorporated in 2013 and is based in Las Vegas, Nevada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for BioAdaptives, Inc., and the rating behind it. BDPT last traded at $0.02; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for BioAdaptives, Inc.. Starting points for BioAdaptives, Inc.: EPS -$0.08, beta 1.15 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for BioAdaptives, Inc.. BioAdaptives, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for BioAdaptives, Inc.. Trailing twelve-month EPS for BioAdaptives, Inc. stands at -$0.08. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for BioAdaptives, Inc.. BioAdaptives, Inc. has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
BioAdaptives, Inc. valued side by side against its closest peers. BioAdaptives, Inc. is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold BioAdaptives, Inc., and how their positions are changing. At a $197,978 market value, institutional positions materially move BioAdaptives, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by BioAdaptives, Inc. executives and directors. Shares of BioAdaptives, Inc. have traded between $0.01 and $0.12 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming BioAdaptives, Inc.. BioAdaptives, Inc. is a $197,978 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming BioAdaptives, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for BioAdaptives, Inc.. Coverage tracks BioAdaptives, Inc. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.